Exact Sciences is paying $75 million up front for U.S. rights to a colorectal cancer blood test developed by rival Freenome. If approved, Freenome’s liquid biopsy will compete with a blood test from Guardant Health.
Cancer rates are climbing among younger Americans, and healthcare leaders are calling for earlier screenings, more convenient testing options and expanded health plan coverage to help catch cases before they’re fatal. From at-home tests to multi-cancer detection tools, stakeholders across the industry are working to boost access to early detection.
Yusuf Qasim, President of Payments Optimization at Zelis, discussed how the company is transforming healthcare payments from a fragmented, patchwork system into a modern, digital infrastructure.
Pfizer drug Braftovi achieved statistically significant and clinically meaningful improvement in overall survival for colorectal cancer patients in a Phase 3 clinical trial. The results will be presented Friday during the annual meeting of the American Society of Clinical Oncology.
Pfizer’s Braftovi received accelerated FDA approval in December as a first-line treatment for metastatic colorectal cancer with a particular genetic mutation. The pharma giant now says the drug has hit primary and secondary goals of its Phase 3 clinical trial.
Geneoscopy received approval for its noninvasive colorectal cancer screening test, which the FDA designated as a breakthrough device. This marks only the second time the FDA has issued an approval for a molecular diagnostic test for colorectal cancer — and the first time the agency has done so for a colorectal cancer test that uses RNA.
FogPharma’s lead program is a peptide that blocks a difficult-to-drug pathway inside of cells. The new financing will go toward an ongoing Phase 1/2 study in advanced solid tumors and support development of pipeline programs for other elusive cancer targets.
In today’s healthcare landscape, your choice of medical billing partner directly impacts your bottom line. What are the best medical billing outsourcing companies, and which one is right for you?
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.
The Hutchmed drug, fruquintinib, is already approved in China for colorectal cancer. Takeda Pharmaceutical gets global rights to the small molecule, which has started a rolling submission with the FDA and is being readied for regulatory submissions in Europe and Japan.
The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match patients with the most effective treatment sooner.
Since it measures the total amount of circulating DNA (ctDNA) in a patient’s bloodstream using a simple blood draw, ctDNA liquid biopsy tests offers oncologists with an accurate, molecular, real-time cancer detection tool. It also helps to determine cancer staging and can help assess how aggressive the treatment regimen should be.
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
Celyad Ocology has voluntarily paused a clinical study evaluating its off-the-shelf CAR T-cell therapy in colorectal cancer following the report of two patient deaths. The investigation is ongoing, but the company said that both patients exhibited “similar pulmonary findings.”
Stand Up To Cancer and Exact Sciences are teaming up to increase colorectal cancer screening awareness and research such that people don't have to die from this preventable disease.
An investigator in the Phase I/II trial of Amgen's AMG 510 said that while data for colorectal cancer indicated low activity as a single agent, it nevertheless represented a doubling in progression-free survival over what is seen from currently available treatments.
Although they're still early, the company presented Phase Ib/II study data showing its PLK1 inhibitor, onvasertib, was able to produce responses in KRAS-mutated metastatic CRC, through a property known as synthetic lethality. KRAS-specific drugs have shown low efficacy in mCRC.
The companies tout the deal as expanding Exact's commercial footprint to 90 countries and creating a leader in the cancer diagnostic space with projected 2020 revenues of $1.6 billion.